company background image
BOLT

Bolt Biotherapeutics NasdaqGS:BOLT Stock Report

Last Price

US$2.27

Market Cap

US$85.4m

7D

-8.8%

1Y

-82.4%

Updated

14 Aug, 2022

Data

Company Financials +
BOLT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BOLT Stock Overview

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system.

Bolt Biotherapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bolt Biotherapeutics
Historical stock prices
Current Share PriceUS$2.27
52 Week HighUS$19.29
52 Week LowUS$1.39
Beta0
1 Month Change-10.28%
3 Month Change46.45%
1 Year Change-82.39%
3 Year Changen/a
5 Year Changen/a
Change since IPO-92.94%

Recent News & Updates

Aug 10

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Bolt Biotherapeutics press release (NASDAQ:BOLT): Q2 GAAP EPS of -$0.61 beats by $0.08. Revenue of $1.39M beats by $0.89M.

Jul 27
We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Apr 12
We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

BOLTUS BiotechsUS Market
7D-8.8%1.2%3.2%
1Y-82.4%-21.7%-10.2%

Return vs Industry: BOLT underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: BOLT underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is BOLT's price volatile compared to industry and market?
BOLT volatility
BOLT Average Weekly Movement14.0%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: BOLT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: BOLT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201591Randy Schatzmanhttps://www.boltbio.com

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade.

Bolt Biotherapeutics Fundamentals Summary

How do Bolt Biotherapeutics's earnings and revenue compare to its market cap?
BOLT fundamental statistics
Market CapUS$85.45m
Earnings (TTM)-US$96.89m
Revenue (TTM)US$3.47m

24.7x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BOLT income statement (TTM)
RevenueUS$3.47m
Cost of RevenueUS$79.13m
Gross Profit-US$75.66m
Other ExpensesUS$21.23m
Earnings-US$96.89m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.57
Gross Margin-2,182.92%
Net Profit Margin-2,795.56%
Debt/Equity Ratio0%

How did BOLT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BOLT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BOLT?

Other financial metrics that can be useful for relative valuation.

BOLT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does BOLT's PS Ratio compare to its peers?

BOLT PS Ratio vs Peers
The above table shows the PS ratio for BOLT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.9x
XGN Exagen
1.9x23.9%US$84.4m
GTH Genetron Holdings
1x24.8%US$84.3m
TCRX TScan Therapeutics
6.8x-2.2%US$84.3m
AZYO Aziyo Biologics
1.9x13.6%US$87.5m
BOLT Bolt Biotherapeutics
24.7x66.9%US$85.4m

Price-To-Sales vs Peers: BOLT is expensive based on its Price-To-Sales Ratio (24.7x) compared to the peer average (2.9x).


Price to Earnings Ratio vs Industry

How does BOLT's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: BOLT is expensive based on its Price-To-Sales Ratio (24.7x) compared to the US Biotechs industry average (17.2x)


Price to Sales Ratio vs Fair Ratio

What is BOLT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BOLT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio24.7x
Fair PS Ratio0x

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BOLT's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BOLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BOLT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BOLT's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Bolt Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


5.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOLT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BOLT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BOLT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BOLT's revenue (66.9% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: BOLT's revenue (66.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BOLT is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Bolt Biotherapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-47.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BOLT is currently unprofitable.

Growing Profit Margin: BOLT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BOLT is unprofitable, and losses have increased over the past 5 years at a rate of 47.7% per year.

Accelerating Growth: Unable to compare BOLT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BOLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: BOLT has a negative Return on Equity (-46.59%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Bolt Biotherapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BOLT's short term assets ($181.3M) exceed its short term liabilities ($18.6M).

Long Term Liabilities: BOLT's short term assets ($181.3M) exceed its long term liabilities ($33.6M).


Debt to Equity History and Analysis

Debt Level: BOLT is debt free.

Reducing Debt: BOLT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BOLT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BOLT has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 39.1% each year.


Discover healthy companies

Dividend

What is Bolt Biotherapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BOLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BOLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BOLT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BOLT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BOLT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Randy Schatzman (67 yo)

3.08yrs

Tenure

US$5,935,603

Compensation

Dr. Randall C. Schatzman, also known as Randy, Ph D., has been the Chief Executive Officer and Director at Bolt Biotherapeutics, Inc. since July 2019. Dr. Schatzman co-founded Alder Biopharmaceuticals Inc....


CEO Compensation Analysis

Compensation vs Market: Randy's total compensation ($USD5.94M) is above average for companies of similar size in the US market ($USD759.99K).

Compensation vs Earnings: Randy's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BOLT's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: BOLT's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bolt Biotherapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Bolt Biotherapeutics, Inc.
  • Ticker: BOLT
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$85.446m
  • Shares outstanding: 37.64m
  • Website: https://www.boltbio.com

Number of Employees


Location

  • Bolt Biotherapeutics, Inc.
  • 900 Chesapeake Drive
  • Redwood City
  • California
  • 94063
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/14 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.